This study compares adherence to breast and ovarian cancer screening recommendations among a population cohort of women at familial risk of breast and/or ovarian cancer. This cross-sectional study included 1039 first-degree female relatives without breast cancer identified from the Ontario site of the Breast Cancer Family Registry. We compared breast and ovarian cancer screening behaviors, using a telephone-administered questionnaire among three groups of women defined by their familial risk (high, moderate, and low) of breast and/or ovarian cancer. Associations between screening behaviors and familial risk were assessed using multinomial regression models adjusted by familial clustering. Women, 40-49 years of age, at moderate or high familial risk were significantly more likely to have had a screening mammogram within the past 12 months [odds ratio (OR): 2.80; 95% confidence interval (CI): 1.40-5.58], and women of less than 50 years of age were more likely to have a clinical breast examination (OR: 1.84; 95% CI: 1.02-3.31) compared with women at low familial risk. Compared with women at low or moderate familial risk, women at high familial risk were significantly more likely to have ever had a genetic test for the BRCA 1/2 genes (OR: 2.67; 95% CI: 1.76-4.05). Although the overall level of adherence among high-risk women is suboptimal in the community, women at a higher familial risk are adhering more often to cancer screening recommendations than women at a lower familial risk.
Notes
Cites: Can Fam Physician. 1999 Jan;45:104-1210889863
Cites: JAMA. 1995 Jan 11;273(2):149-547799496
Cites: Ann Intern Med. 2000 Dec 5;133(11):855-6311103055
Cites: Cancer Epidemiol Biomarkers Prev. 1995 Apr-May;4(3):269-737606202
Cites: JAMA. 1996 Jun 26;275(24):1885-928648868
Cites: Health Psychol. 1996 Nov;15(6):423-98973921
Cites: JAMA. 1997 Mar 26;277(12):997-10039091675
Cites: Int J Cancer. 1997 May 29;71(5):800-99180149
Cites: Am J Epidemiol. 1998 Apr 1;147(7):652-99554604
Cites: Cancer Epidemiol Biomarkers Prev. 2005 Oct;14(10):2340-516214914
Cites: Eur J Cancer Prev. 2005 Dec;14(6):503-1116284494
Cites: BMC Cancer. 2006;6:21016916448
Cites: Fam Cancer. 2006;5(4):359-6816817030
Cites: J Womens Health (Larchmt). 2007 May;16(4):526-3417521256
Cites: JAMA. 2008 May 14;299(18):2151-6318477782
Cites: Genet Med. 2008 Aug;10(8):621-518641520
Cites: J Med Genet. 2009 Sep;46(9):593-718413372
Cites: Ann Intern Med. 2009 Nov 17;151(10):727-37, W237-4219920273
Cites: Breast Cancer Res Treat. 2010 Nov;124(2):509-1920364401
Cites: Eur J Cancer Prev. 2011 Jul;20(4):255-6221467941
Cites: Cancer Epidemiol Biomarkers Prev. 2000 Jan;9(1):103-1110667470
Cites: J Med Genet. 2000 Mar;37(3):203-910699057
Cites: Breast Cancer Res Treat. 2000 Jan;59(2):101-1110817345
Cites: Lancet. 2000 Jun 10;355(9220):2015-2010885351